The PALOMA-1/TRIO-18 trial was an open-label randomized phase 2 study that enrolled postmenopausal women with metastatic HR-positive HER2-negative BC who had not received previous systemic treatment in the advanced disease setting. The gene discussed is ERBB2; the disease is breast cancer.